Dihexa vs Semax
Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board
- Semax has small human studies and is an approved medicine in Russia. Dihexa has never been tested in people in any published study 3.
- Both are sold as brain-growth compounds: semax through BDNF, dihexa through HGF and c-Met. The papers behind dihexa's mechanism were retracted 7 3.
- Dihexa's advertised target, c-Met, drives cancer growth when overactive 10; semax's studies point to a different growth factor, BDNF 2.
Side by side
Dihexa Low and semax Medium are both described as compounds that build brain connections 1 2. They differ sharply in how much is known 3. The table is read from our encyclopedia entries.
| Field | Dihexa | Semax |
|---|---|---|
| Encyclopedia entry | Dihexa Full entry | Semax Full entry |
| Molecule class | Peptidomimetic | Peptide |
| Category | Cognitive | Cognitive |
| FDA status | Research Chemical | Not FDA Approved |
| Approved elsewhere | None recorded | Russia |
| Evidence grade | Low | Medium |
| Half-life | Undetermined in humans | Not measured in humans |
| Formula | C27H44N4O5 | C37H51N9O10S |
| Molecular weight | 504.7 g/mol | 813.9 g/mol |
| WADA 2026 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| WADA 2027 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| In one line | A modified dipeptide built from angiotensin IV to reach the brain by mouth: rodent memory studies only, no human data, and the paper tying it to HGF/c-Met is retracted. | A synthetic ACTH-derived heptapeptide approved in Russia for stroke rehabilitation and optic nerve disorders, with documented BDNF upregulation and broad nootropic activity. |
| Mechanism | Reported to augment hepatocyte growth factor (HGF) binding to the c-Met receptor, promoting synaptogenesis and dendritic spine formation in hippocampal neurons. Promoted as orders of magnitude more potent than BDNF in preclinical synaptogenesis assays. Because c-Met activation is oncogenic in many cancers, there is a theoretical concern about tumor promotion with chronic use. | In rats, a single dose raised hippocampal BDNF protein 1.4-fold and exon III BDNF mRNA threefold, with more trkB activation, and intranasal doses raised basal-forebrain BDNF within three hours; it binds specific sites there. In mice it increased striatal serotonin turnover and strongly amplified amphetamine's dopamine and locomotor effects. In rat stroke models it shifts immune-response gene expression. How these findings translate to people is not established. |
| Sources in the entry | 7 | 14 |
| Study cards | 2 | 12 |
| Dosage page | None | Dosage page |
Semax: small studies, a Russian approval
Semax is a synthetic ACTH fragment given as nasal drops and approved as a medicine in Russia 3. In rats a single nasal dose raised hippocampal BDNF by up to 1.4 times and activated its receptor (animal evidence) 2. In 110 patients after ischaemic stroke, two courses alongside rehabilitation raised plasma BDNF (human study; the abstract does not say how patients were assigned) 4, and an imaging study in 24 healthy adults found changes in a brain network 5 to 20 minutes after a nasal dose 5. That is thin evidence, but it is human evidence.
Dihexa: rodents only, and a mechanism withdrawn
Dihexa was introduced in 2013 as an orally active, brain-penetrant angiotensin IV analogue that reversed memory deficits in rats 1; in 2021 the journal issued a notice of concern about that paper 6. Its claimed mechanism, binding HGF and boosting c-Met, came from papers published in 2011, 2012 and 2014 that PubMed now records as retracted 3, the 2014 one with a notice in April 2025 7. Another group found dihexa restored spatial learning in Alzheimer's-model mice (animal evidence) 8, and in a Huntington's-like rat model it did not help (animal evidence) 9. No published study has given dihexa to a person.
BDNF versus c-Met: why the target matters
Both compounds are sold as growth-factor boosters, but the growth factors differ. Semax's studies point to BDNF, a growth factor for nerve connections. Dihexa was promoted as strengthening HGF and its receptor c-Met, and c-Met is a proto-oncogene: a 2021 review describes hyperactive HGF/c-MET signalling as a hallmark of many cancers, involved in growth, spread and drug resistance (review) 10. No study has shown that dihexa causes cancer, and we found none that looked. It is a theoretical concern grounded in the cancer biology that review describes.
The closest human test of the HGF idea
A different HGF/MET modulator, fosgonimeton, reached a 287-person phase 2/3 Alzheimer's trial and missed its primary and secondary endpoints (p = 0.70 on the main combined score), with more people stopping it because of side effects than placebo (human trial) 11. It is not dihexa, but it is the largest human test of boosting HGF/MET for cognition that we found.
How the differences add up (as of October 27, 2026)
On every measure the comparison favours semax: some human data, an approval in one country 3, and a mechanism (BDNF) that is not the cancer-linked c-Met pathway. Dihexa has no human data, its mechanism papers were retracted, and its target raises a cancer question no one has studied. Neither is FDA-approved. Dihexa is in no FDA compounding category and is due for review by FDA's compounding committee by the end of February 2027; for athletes it falls under WADA's S0, while semax's status is unsettled 3. Our dihexa safety guide covers the retractions in detail. Doses on this page are those in our entries' sources, not recommendations.
Frequently asked questions
Is dihexa stronger than semax?
Dihexa has only cell and animal data, so there is no human comparison. Semax has small human studies and is approved in Russia; dihexa has never been tested in people.
Is dihexa safe?
Unknown. No human study exists, its mechanism papers were retracted, and its advertised target, c-Met, is a cancer-linked pathway.
Do semax and dihexa work the same way?
No. Semax's studies point to BDNF; dihexa was promoted as boosting HGF and c-Met, though the papers behind that mechanism were retracted.
Related on Grey Peptides
Sources
- McCoy, A. T., et al. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther, 344(1), 141-54. PMID: 23055539
- Dolotov, O. V., et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res, 1117(1), 54-60. PMID: 16996037
- Grey Peptides dataset records for dihexa and semax (FDA and compounding status, WADA 2026 and 2027 status, retraction notes for the 2011, 2012 and 2014 papers, studied doses as sourced on each entry); read October 27, 2026.
- Gusev, E. I., et al. (2018). [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova, 118(3. Vyp. 2), 61-68. PMID: 29798983
- Lebedeva, I. S., et al. (2018). Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med, 165(5), 653-656. PMID: 30225715
- Journal of Pharmacology and Experimental Therapeutics (2021). Notice of Concern: McCoy AT, et al. (2013), Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents, 344: 141-154. J Pharmacol Exp Ther, 378(3), 313. PubMed record 34551989, read October 27, 2026. PubMed
- Benoist, C. C., et al. (2025). Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. J Pharmacol Exp Ther, 392(4), 103567. PMID: 40312093
- Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci, 11(11). PMID: 34827486
- Wells, R. G., et al. (2024). Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. J Huntingtons Dis, 13(1), 55-66. PMID: 38489193
- Fu, J., et al. (2021). HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene, 40(28), 4625-4651. PMID: 34145400
- Porsteinsson, A. P., et al. (2025). Fosgonimeton in mild-to-moderate Alzheimer's disease. J Alzheimers Dis Rep, 9, 25424823251405817. PMID: 41393340
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead